LOS ANGELES, CA–(Marketwired – May 9, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, 2017 and provided other business updates.
May 09, 2017 at 04:58PM
from
No comments:
Post a Comment